Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 6, 2019
Daily News
November 6, 2019
- Japan Industry Asks for AMED Funding of 50 Billion Yen to Build Big Data Platform
November 6, 2019
- 8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
- Aso, CEFP Members Talked about Aducanumab at Oct. 28 Meeting, Minutes Reveal
November 6, 2019
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
- Treakisym Succeeds in PIII DLBCL Study, Japan Filing Eyed in H1 2020: SymBio
November 6, 2019
- Takeda to Divest Non-Core Assets Sold in Russia, Former Soviet States
November 6, 2019
- Daiichi Sankyo Sues Seattle Genetics over ADC Technology
November 6, 2019
- Eisai Transfers Tazemetostat Royalty Rights Outside Japan to US Firm
November 6, 2019
- Crysvita Accepted for Review in Europe for Additional Adult Use
November 6, 2019
- Torii Acquires Japan Marketing Rights to BioCryst’s HAE Treatment
November 6, 2019
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…